Has Pooja Kinkhabwala, DO received payments from drug or device companies?

Yes. Drug and device makers reported $68,168 in general payments to Pooja Kinkhabwala, DO across 954 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pooja Kinkhabwala, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pooja Kinkhabwala, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pooja Kinkhabwala, DO

Endocrinology, Diabetes & Metabolism · Merrillville, INNPI 1194104059

Payments from drug & device makers

$68,168in general payments, 2019–2025

Across 954 payments — averaging $71.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kyowa Kirin, Inc.$33K
Abbott$9K
Recordati_rare_diseases_inc.$7K
Amgen$4K
AstraZeneca$2K
Lilly USA, LLC$1K
plus $12K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kyowa Kirin, Inc.	65	$32,574
Abbott	54	$8,715
Recordati_rare_diseases_inc.	172	$7,176
Amgen(2 entities)	68	$3,714
AstraZeneca(2 entities)	40	$2,300
Lilly USA, LLC	72	$1,333
Novartis	27	$1,101
Insulet Corporation	30	$1,057
Sanofi-aventis U.S. LLC	31	$919
Amarin Pharma, Inc.	25	$792
Boehringer Ingelheim	28	$673
Xeris Pharmaceuticals, Inc.	30	$601
Medtronic	6	$570
Dexcom, Inc.	40	$533
Radius Health, Inc.	17	$498
Novo Nordisk	19	$421
Esperion Therapeutics, Inc.	15	$418
Corcept Therapeutics	17	$382
Mannkind Corporation	9	$364
Zealand Pharma US, Inc.	11	$333
Johnson & Johnson	7	$323
EUSA Pharma (US) LLC	30	$320
AbbVie	18	$306
Bayer	10	$226
GRT US Holding, Inc.	11	$176
Tandem Diabetes Care, Inc.	3	$152
Shire North American Group Inc	3	$138
IBSA Pharma Inc.	9	$128
Clarus Therapeutics Inc.	1	$125
Amneal Pharmaceuticals LLC	7	$120
BD	6	$113
Cequr Corporation	1	$110
Averitas Pharma Inc.	4	$107
Ascensia Diabetes Care US Inc.	5	$107
Regeneron Healthcare Solutions, Inc.	5	$102
Embecta Corp.	5	$93
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	4	$83
Acorda Therapeutics, Inc	3	$71
Jazz Pharmaceuticals Inc.	3	$67
Lifescan, Inc.	3	$63
Biogen	2	$59
Ultragenyx Pharmaceutical Inc.	3	$52
Eisai Inc.	2	$50
TG Therapeutics, Inc.	3	$46
Antares Pharma, Inc.	2	$42
Sequel Med Tech, LLC	2	$42
Axsome Therapeutics, Inc.	2	$41
Amryt Pharma Holdings Ltd	2	$32
Banner Life Sciences, LLC	2	$32
Upsher-smith Laboratories LLC	2	$28
EMD Serono, Inc.	2	$27
Alnylam Pharmaceuticals Inc.	1	$26
Corium, LLC	1	$25
Sanofi	1	$24
Kowa Pharmaceuticals America, Inc.	1	$24
SK Life Science, Inc.	1	$22
Takeda Pharmaceuticals U.S.A., Inc.	1	$22
Merck	1	$21
Chiesi USA, Inc.	1	$20
Daiichi Sankyo Inc.	1	$19

How this compares

$68,168 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana →

Medicare billing

Part B allowed, 2024

$61,656

Medicare patients

225

Services billed

723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Merrillville

Nihad MuhrezMerrillville$271K
Cydney Bullock-TiptonMerrillville$4K
Richard LongleyMerrillville$3K
Carmella Evans-MolinaIndianapolis$6.3M
Isaiah PittmanTerre Haute$1.5M
Ernest AsamoahIndianapolis$959K
Sana MeahMunster$829K
James MaloneIndianapolis$822K
Erica KretchmanRichmond$636K
Emily VeenemanSeymour$583K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →